List of Zynrelef Kit drug patents

Zynrelef Kit is owned by Heron Theraps Inc.

Zynrelef Kit contains Bupivacaine; Meloxicam.

Zynrelef Kit has a total of 15 drug patents out of which 0 drug patents have expired.

Zynrelef Kit was authorised for market use on 12 May, 2021.

Zynrelef Kit is available in solution, extended release;periarticular dosage forms.

Zynrelef Kit can be used as treatment of postsurgical pain providing analgesia to a patient for up to 72 hours, for example, after foot and ankle, small-to-medium open abdominal, and lower extremity total joint arthroplasty surgical procedures via instillation, treatment of postsurgical pain providing analgesia to a patient for up to 72 hours, for example, after bunionectomy, open inguinal herniorrhaphy, or total knee arthroplasty via soft tissue or periarticular instillation.

The generics of Zynrelef Kit are possible to be released after 20 April, 2035.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9913909 HERON THERAPS INC Compositions of a polyorthoester and an aprotic solvent
Mar, 2034

(11 years from now)

US11253504 HERON THERAPS INC Compositions of a polyorthoester and an aprotic solvent
Mar, 2034

(11 years from now)

US10398686 HERON THERAPS INC Compositions of a polyorthoester and an aprotic solvent
Mar, 2034

(11 years from now)

US9744163 HERON THERAPS INC Compositions of a polyorthoester and an aprotic solvent
Mar, 2034

(11 years from now)

US9592227 HERON THERAPS INC Compositions of a polyorthoester and an aprotic solvent
Mar, 2034

(11 years from now)

US10632199 HERON THERAPS INC Long-acting polymeric delivery systems
Apr, 2035

(12 years from now)

US10898575 HERON THERAPS INC Long-acting polymeric delivery systems
Apr, 2035

(12 years from now)

US11083797 HERON THERAPS INC Long-acting polymeric delivery systems
Apr, 2035

(12 years from now)

US11083730 HERON THERAPS INC Long-acting polymeric delivery systems
Apr, 2035

(12 years from now)

US10980886 HERON THERAPS INC Compositions of a polyorthoester and an organic acid excipient
Apr, 2035

(12 years from now)

US11413350 HERON THERAPS INC Long-acting polymeric delivery systems
Apr, 2035

(12 years from now)

US9694079 HERON THERAPS INC Long-acting polymeric delivery systems
Apr, 2035

(12 years from now)

US9801945 HERON THERAPS INC Long-acting polymeric delivery systems
Apr, 2035

(12 years from now)

US10213510 HERON THERAPS INC Long-acting polymeric delivery systems
Apr, 2035

(12 years from now)

US10098957 HERON THERAPS INC Long-acting polymeric delivery systems
Apr, 2035

(12 years from now)

Exclusivity Exclusivity Expiration
New Product (NP) May 12, 2024

Drugs and Companies using BUPIVACAINE; MELOXICAM ingredient

Market Authorisation Date: 12 May, 2021

Treatment: Treatment of postsurgical pain providing analgesia to a patient for up to 72 hours, for example, after bunionectomy, open inguinal herniorrhaphy, or total knee arthroplasty via soft tissue or periarticular instillation; Treatment of postsurgical pain providing analgesia to a patient for up to 72 hours, for example, after foot and ankle, small-to-medium open abdominal, and lower extremity total joint arthroplasty surgical procedures via instillation

Dosage: SOLUTION, EXTENDED RELEASE;PERIARTICULAR

More Information on Dosage

ZYNRELEF KIT family patents

29

United States

12

Japan

6

China

6

European Union

5

Korea, Republic of

5

Australia

3

Canada

2

RS

2

Poland

2

Lithuania

2

Spain

2

Mexico

2

Slovenia

2

Hungary

2

Portugal

2

Croatia

2

Taiwan, Province of China

2

Denmark

1

Brazil

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in